The size of the global HbA1c testing market is anticipated to grow at 11% CAGR from 2024 to 2032 and be worth USD 4.60 billion by 2032 from USD 2 billion in 2024
HbA1c is a modified form of an oxygen-carrying pigment in red blood cells called hemoglobin. Most hemoglobin is in HbA form, but a small fraction transforms into HbA1 during their lifespans. In further findings, scientists discovered in the 1950s that HbA1 could further be separated into HbA1a, HbA1c, and HbA1c. Patients with diabetes have an alarmingly high level of HbA1c in their bodies as its formation occurs only during a process called glycosylation, which involves converting glucose into glycogen for storage purposes.
The number of people affected by diabetes increases exponentially daily due to poor dietary choices, lack of physical activities, and high stress levels. As a result, physicians are increasingly prescribing HbA1c tests to their patients, which is expected to drive the market revenue for HbA1c Testing. Moreover, the emergence of point of care and other new devices to lower the cost of diabetes testing is further expected to aid the HbA1c Testing Market growth.
The senior population is increasing continually, leading to a rise in diabetic patients' accounts worldwide. Innovative testing procedures and handheld devices due to technological advancements are expected to provide lucrative opportunities for the HbA1c testing market stakeholders. The increased scope of medical tourism in developing countries is likely to boost the HbA1c testing market opportunities. Growing awareness among people to manage diabetes efficiently is expected to offer growth opportunities for the key players in the market.
Increasing demand for handheld analyzers and proliferated diagnostic laboratories in remote locations of countries like India and China are expected to provide lucrative growth opportunities for the HbA1c market during the forecast period. In addition, the rise in the affordability of testing devices in hospitals due to patient footfalls will likely provide more opportunities for the HbA1c testing market's growth during the forecast period. Prevalence for early disease diagnosis among people also lavishes the market's growth.
The devices used for testing are costly. The adoption of these technologies is minimal in developing countries, which is expected to limit the growth of the HbA1c testing market. Manufacturing costs of these devices are high resulting in limited production of HbA1c testing devices, posing a challenge to the key players in the HbA1c market. Another major challenge is inaccuracies in the testing due to discrepancies in interpretations expected to resist the market's growth during the forecast period. Stringent rules and regulations by the government may also negatively impact the HbA1c Testing Market's growth rate.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Covered |
By Technology, Type, End-User, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Key Market Players |
Transasia Biomedicals Ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, and Trinity Biotech plc. |
The affinity binding chromatography segment held the largest share in the HbA1c testing market in 2023, owing to the increasing investments and support.
The Ion-Exchange HPCL segment is another lucrative segment in the global HbA1C market. Due to the various advantages over other technologies, Ion exchange is most widely used for HbA1c testing. The HPLC consumes less time, recognizes variants, and is utilized in Point-of-care settings.
The Turbidimetric inhibition immunoassay is anticipated to grow healthy during the forecast period. The segment provides accurate results; it is cost-effective and quick swiftness.
The benchtop devices segment had the largest share of the global market in 2023, and the lead of the segment is expected to continue throughout the forecast period due to its fast and accurate results.
The homecare segment is projected to account for most of the market share during the forecast period due to the rising popularity of home care services, a crucial factor governing this segment's growth. Furthermore, escalating preference for diabetic patients regarding self-monitoring HbA1clevels and the capability of the tests to provide quick outputs favors the segment to excel more.
As of 2023, North America accounted for the largest share of the HbA1c Testing market, followed by Europe and the Asia Pacific. However, the Asia Pacific is projected to register the highest growth rate in the coming years due to diabetes's growing cases of diabetes. Moreover, low healthcare costs are crucial in boosting medical tourism in the region, which will aid market growth.
The promising companies leading the Global HbA1c Testing Market profiled in this report are Transasia Biomedicals Ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, and Trinity Biotech plc.
By Technology
By Type
By End User
By Region
Frequently Asked Questions
The global HbA1c testing market was valued at USD 1.8 billion in 2023.
The North American region was the market leader in the global market in 2023.
Based on the technology, the affinity binding chromatography segment dominated the market in 2023.
Transasia Biomedicals Ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, and Trinity Biotech plc are some of the noteworthy companies in the HbA1c testing market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region